Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

For its part, Abecma made $89 million in the second quarter, up 36% on the previous quarter with the increase driven by "expanded capacity and vector supply," according to BMS.